Bring cutting-edge technology into hospital wards faster: these three types of innovations can apply for pre-pricing project initiation.

The National Healthcare Security Administration issued the Notice on Piloting the Pre-approval System for Medical Service Price Items of High-level New Technologies and New Products on the 15th, explicitly exploring the establishment of a pre-approval system for medical service price items to promote the large-scale application of major innovative achievements. Previously, new technologies, new devices, and new consumables only started the price approval process after passing review by health authorities or drug regulatory authorities. By exploring the pre-approval system, the key node of price support is moved forward to the R&D and clinical research stages. Dong Zhaohui, Deputy Director of the Department of Pharmaceutical Price and Tendering and Procurement of the National Healthcare Security Administration: The pre-approval system focuses on innovation in three situations. New technologies with great clinical value and breakthroughs in diagnosis and treatment methods. New equipment that meets major clinical needs, effectively solves diagnosis and treatment difficulties in key areas, and improves diagnosis and treatment efficiency and precision. New consumables that fill diagnosis and treatment gaps, focus on patient benefits, and change surgical plans. The notice also clarifies that ordinary iterative upgraded equipment, routine reagents, and products that can be directly charged as consumables or drugs are not within the scope of pre-approval.